XR Securities’s Bristol-Myers Squibb BMY Stock Holding History

XR Securities’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,500	Closed	-$728K	–	388
2023 Q1	$728K	Sell	10,500 -14,000	-57%	-$987K	0.02%	220
2022 Q4	$1.76M	Buy	24,500 +7,300	+42%	+$550K	0.17%	113
2022 Q3	$63K	Sell	17,200 -32,600	-65%	-$2.36M	0.03%	226
2022 Q2	$335K	Buy	+49,800	New	+$3.79M	0.11%	125
2022 Q1	–	Sell	-11,400	Closed	-$11K	–	366
2021 Q4	$11K	Buy	+11,400	New	+$669K	﹤0.01%	402
2021 Q1	–	Sell	-10,000	Closed	-$19K	–	477
2020 Q4	$19K	Buy	+10,000	New	+$615K	﹤0.01%	367
2020 Q2	–	Sell	-11,000	Closed	-$31K	–	245
2020 Q1	$31K	Sell	11,000 -2,000	-15%	-$122K	﹤0.01%	163
2019 Q4	$87K	Sell	13,000 -5,100	-28%	-$292K	0.01%	151
2019 Q3	$64K	Buy	+18,100	New	+$851K	0.01%	158
2019 Q2	–	Sell	-26,000	Closed	-$17K	–	273
2019 Q1	$17K	Buy	26,000 +3,100	+14%	+$154K	﹤0.01%	229
2018 Q4	$8K	Sell	22,900 -6,700	-23%	-$360K	﹤0.01%	282
2018 Q3	$55K	Buy	+29,600	New	+$1.76M	0.01%	240

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

XR Securities's BMY Position: Q1 2024 in Review

XR Securities sold out of Bristol-Myers Squibb (BMY) in Q1 2024, closing a stake of 3,902 shares — an estimated $200K sold.

XR Securities first reported a position in BMY in Q2 2019 and held it in 9 quarters. The position peaked at $1.44M in Q4 2019. 2,332 funds tracked by Wall St. Rank hold BMY as of Q1 2024.

XR Securities reported no remaining Bristol-Myers Squibb position as of Q1 2024 after selling out during the quarter.
XR Securities sold 3,902 Bristol-Myers Squibb shares in Q1 2024, an estimated $200K.
XR Securities first reported a position in Bristol-Myers Squibb in Q2 2019 and held it in 9 quarters.
XR Securities's Bristol-Myers Squibb position peaked at $1.44M in Q4 2019.
2,332 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2024.

Based on XR Securities's 13F filing for Q1 2024, filed 8 May 2024.